Methods for the Inclusion of Real-World Evidence in a Rare Events Meta-Analysis of Randomized Controlled Trials.

J Clin Med

Chinese Evidence-Based Medicine Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu 610041, China.

Published: February 2023

Background: Many rare events meta-analyses of randomized controlled trials (RCTs) have lower statistical power, and real-world evidence (RWE) is becoming widely recognized as a valuable source of evidence. The purpose of this study is to investigate methods for including RWE in a rare events meta-analysis of RCTs and the impact on the level of uncertainty around the estimates.

Methods: Four methods for the inclusion of RWE in evidence synthesis were investigated by applying them to two previously published rare events meta-analyses: the naïve data synthesis (NDS), the design-adjusted synthesis (DAS), the use of RWE as prior information (RPI), and the three-level hierarchical models (THMs). We gauged the effect of the inclusion of RWE by varying the degree of confidence placed in RWE.

Results: This study showed that the inclusion of RWE in a rare events meta-analysis of RCTs could increase the precision of the estimates, but this depended on the method of inclusion and the level of confidence placed in RWE. NDS cannot consider the bias of RWE, and its results may be misleading. DAS resulted in stable estimates for the two examples, regardless of whether we placed high- or low-level confidence in RWE. The results of the RPI approach were sensitive to the confidence level placed in RWE. The THM was effective in allowing for accommodating differences between study types, while it had a conservative result compared with other methods.

Conclusion: The inclusion of RWE in a rare events meta-analysis of RCTs could increase the level of certainty of the estimates and enhance the decision-making process. DAS might be appropriate for inclusion of RWE in a rare event meta-analysis of RCTs, but further evaluation in different scenarios of empirical or simulation studies is still warranted.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964527PMC
http://dx.doi.org/10.3390/jcm12041690DOI Listing

Publication Analysis

Top Keywords

rare events
24
inclusion rwe
20
events meta-analysis
16
rwe rare
16
meta-analysis rcts
16
rwe
12
methods inclusion
8
real-world evidence
8
randomized controlled
8
controlled trials
8

Similar Publications

Introduction: Eculizumab is a C5 complement inhibitor approved by the FDA for the targeted treatment of four rare diseases, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and aquaporin-4 immunoglobulin G-positive optic neuromyelitis optica spectrum disorders (AQP4-IgG+NMOSD). The current study was conducted to assess real-world adverse events (AEs) associated with eculizumab through data mining of the FDA Adverse Event Reporting System (FAERS).

Methods: Disproportionality analyses, including Reporting Ratio Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS) algorithms were used to quantify the signals of eculizumab-associated AEs.

View Article and Find Full Text PDF

Background: Osteoarthritis (OA) is a prevalent joint disorder requiring innovative treatment approaches.

Aim: To evaluate the use of nanofat, a specialized form of adipose tissue-derived cells, in the treatment of OA, by examining its efficacy, safety profile, mechanisms of action, comparative effectiveness, and long-term outcomes.

Methods: A comprehensive review of preclinical studies, clinical trials, and investigations was conducted.

View Article and Find Full Text PDF

Introduction: Pembrolizumab is an immune checkpoint inhibitor widely administered for the treatment of various malignancies. Despite its effectiveness, its distinctive mechanism of action may lead to immune-related adverse events, most frequently affecting cutaneous tissues. Hair-related adverse events, although uncommon, include conditions such as alopecia areata and alterations in hair texture or type.

View Article and Find Full Text PDF

Cold climate-driven convergent evolution among angiosperms.

Plant Commun

January 2025

State Key Laboratory of Subtropical Silviculture, College of Forestry and Biotechnology, Zhejiang A&F University; Hangzhou 311300, China; Zhejiang International Science and Technology Cooperation Base for Plant Germplasm Resources Conservation and Utilization, Zhejiang A&F University; Hangzhou 311300, China; Provincial Key Laboratory for Non-wood Forest and Quality Control and Utilization of Its Products, Zhejiang A&F University, Hangzhou 311300, China. Electronic address:

Convergent and parallel evolution occur more frequently than previously thought. Here, we focus on the evolutionary adaptations of angiosperms to sub-zero temperatures. We begin by introducing the research history of convergent and parallel evolution, defining all independent similarities as convergent evolution.

View Article and Find Full Text PDF

Surgical treatment of anomalous aortic origin of the coronary artery in paediatric patients: a Chinese single-center experience.

BMC Surg

January 2025

Department of Cardiothoracic Surgery, Heart Center, School of Medicine, Shanghai Children's Medical Center, Shanghai Jiaotong University, Shanghai, China.

Purpose: An anomalous aortic origin of the coronary artery (AAOCA) is a rare congenital heart disease. Some high-risk anatomical structures are at risk of inducing cardiogenic shock or even sudden death. This article summarizes our surgical experience with AAOCA in paediatric patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!